Form 4: Vertex Pharmaceuticals CEO Reshma Kewalramani Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
Reshma Kewalramani, CEO of Vertex Pharmaceuticals, disposed of 9,386 shares of common stock on February 24, 2025, to cover tax obligations.
Summary
- On February 24, 2025, Reshma Kewalramani, the CEO and President of Vertex Pharmaceuticals, disposed of 9,386 shares of common stock.
- The transaction was executed at a price of $483.28 per share.
- This disposal was likely to cover tax obligations related to vesting of stock or option exercises.
- Following the transaction, Kewalramani directly owns 119,994 shares of Vertex Pharmaceuticals common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects a routine transaction related to tax obligations, which is a normal part of executive compensation. It doesn't inherently indicate a positive or negative outlook for the company.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. Disposals to cover tax obligations are common and don't necessarily indicate a negative outlook on the company.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine disposal of shares by an executive for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 02/24/2025 | Date of stock disposal transaction |
| 02/26/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.